EcoDrugPlus

Serpin Family C Member 1

Ensembl ID : ENSDCDG00000035131
Gene Symbol: SERPINC1
3 Cross references
202 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSDCDG00000016882
Gene Symbol: SIGMAR1
3 Cross references
206 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSDCDG00000033004
Gene Symbol: SIRT1
3 Cross references
159 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSDCDG00000027861
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B-Like

Ensembl ID : ENSDCDG00000018388
Gene Symbol: LOC114784275
3 Cross references
263 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSDCDG00000028915
Gene Symbol: LOC114789045
3 Cross references
245 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSDCDG00000019859
Gene Symbol: LOC114779022
3 Cross references
263 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSDCDG00000014906
Gene Symbol: LOC114797850
3 Cross references
263 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSDCDG00000003232
Gene Symbol: SCN4A
3 Cross references
188 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSDCDG00000028568
Gene Symbol: LOC114797748
3 Cross references
204 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSDCDG00000003533
Gene Symbol: LOC114785999
3 Cross references
250 Possible Orthologues:

Sodium/hydrogen Exchanger 3-Like

Ensembl ID : ENSDCDG00000028338
Gene Symbol: LOC114769882
3 Cross references
238 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).